Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316

Summary

Sun Pharma Advanced Research company Limited has developed a dry powder inhaler of compound SPARC1316 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients.

Timeline

Start

2014-01

Primary completion

2014-11

Completion

2014-11

Drugs

Indications